articleTop 1% cited
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · Vol. 27(suppl 5) · pp. v1–v27
Silvia Novello✉(Ospedale San Luigi Gonzaga)Fabrice Barlési(Aix-Marseille Université)Raffaele Califano(Manchester University NHS Foundation Trust)Tanja Čufer(University Clinic of Pulmonary and Allergic Diseases Golnik)Simon Ekman(Karolinska University Hospital)Matteo Giaj Levra(Centre Hospitalier Universitaire de Grenoble)Keith M. Kerr(Aberdeen Royal Infirmary)Sanjay Popat(Royal Marsden Hospital)Martin Reck(LungenClinic Grosshansdorf)Suresh Senan(Amsterdam UMC Location Vrije Universiteit Amsterdam)G.V. Simo(Universidad de Salamanca)Johan Vansteenkiste(KU Leuven)Solange Peters(University Hospital of Lausanne)
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesMedicineLung cancerOncologyClinical PracticeCancerInternal medicineFamily medicine
Citations
2,632
FWCI
201.66
field-weighted impact
References
247
Percentile
100%
vs. same field & year
Citations per year
Cited by
Current and Future Development in Lung Cancer Diagnosis
International Journal of Molecular Sciences · 2021 · 906 citations
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Cancers · 2020 · 498 citations
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology · 2019 · 1,645 citations
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
British Journal of Cancer · 2019 · 1,311 citations
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,299 citations
References
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery
Annals of Neurology · 1993 · 1,048 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
European Journal of Cancer · 2008 · 756 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · 3,206 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.